Efficacy and safety of bevacizumab biosimilar compared with reference bevacizumab in locally advanced and advanced non-small cell lung cancer patients: A retrospective study

Overview of attention for article published in Frontiers in oncology, January 2023

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (84th percentile)
High Attention Score compared to outputs of the same age and source (96th percentile)

Mentioned by

news: 1 news outlet

twitter: 2 X users

Citations

dimensions_citation: 4 Dimensions

Readers on

mendeley: 7 Mendeley

Summary News X Dimensions citations

So far, Altmetric has seen 1 news story.

Study: Bevacizumab Biosimilar Is Equivalent in Efficacy for Patients with NSCLC

Pharmacy Times, 20 Mar 2023

The treatment shows an acceptable toxicity profile and no new adverse events, according to results of analysis.

This page shows the most recent news stories that mention this research output.

Click here to find out how to access more activity.